4.7 Review

Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB

期刊

PHARMACEUTICS
卷 13, 期 8, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics13081183

关键词

neurological disorders; BBB; nano drug delivery; SLN

资金

  1. Ministry of Science and Technology of Taiwan [MOST-106-2320-B-038-049-MY3, MOST-108-2314-B-038-022]

向作者/读者索取更多资源

The blood-brain barrier (BBB) is crucial in protecting and maintaining homeostasis in the brain, making it an interesting target for drug delivery in the treatment of neurological conditions. Advances in nanodrug delivery have led to solid lipid nanoparticles (SLNs) emerging as a promising drug carrier system for delivering therapeutic drugs across the BBB to target CNS disorders more effectively and with reduced toxicity.
The blood-brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据